KRT20, keratin 20, 54474

N. diseases: 559; N. variants: 1
Source: ALL
Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C0079731
Disease: B-Cell Lymphomas
B-Cell Lymphomas
0.100 Biomarker group BEFREE Obinutuzumab is a novel glycoengineered, type-II anti-CD20 monoclonal antibody that was recently developed to treat follicular lymphoma (FL), the most prevalent subtype of indolent B-cell lymphoma. 31848991 2020
CUI: C0079731
Disease: B-Cell Lymphomas
B-Cell Lymphomas
0.100 AlteredExpression group BEFREE CD52 and CD20 are co-expressed on the cell surface of malignant B cells in B-cell non-Hodgkin lymphoma (B-NHL) and chronic lymphocytic leukemia (CLL) and increased expression of both antigens is detected on dividing or recently divided cells ("proliferative fraction") in CLL. 30145356 2019
CUI: C0079731
Disease: B-Cell Lymphomas
B-Cell Lymphomas
0.100 Biomarker group BEFREE Monoclonal antibodies targeting CD20 are central in the treatment of B-cell lymphomas. 31669559 2019
CUI: C0079731
Disease: B-Cell Lymphomas
B-Cell Lymphomas
0.100 Biomarker group BEFREE Soon after the anti-CD20 monoclonal antibody rituximab began to change the management of indolent and aggressive B cell lymphomas, development of alternative antibodies - including chemoimmunoconjugates - was undertaken. 30668192 2019
CUI: C0079731
Disease: B-Cell Lymphomas
B-Cell Lymphomas
0.100 Biomarker group BEFREE These findings indicate that the number of NK cells in peripheral blood may affect the outcome of patients with B-cell non-Hodgkin lymphoma receiving anti-CD20-based immunochemotherapy. 31053601 2019
CUI: C0079731
Disease: B-Cell Lymphomas
B-Cell Lymphomas
0.100 AlteredExpression group BEFREE CD20 expression by malignant lymphocyte-predominant cells, a tendency for late relapses, and the risk of transformation to aggressive large B-cell lymphoma are characteristic features with important implications for treatment and follow-up. 30485408 2019
CUI: C0079731
Disease: B-Cell Lymphomas
B-Cell Lymphomas
0.100 AlteredExpression group BEFREE The majority of B cell lymphomas express CD20, making it a valuable target both for antibody-based therapy and imaging. 30456475 2019
CUI: C0079731
Disease: B-Cell Lymphomas
B-Cell Lymphomas
0.100 Biomarker group BEFREE Specificity of binding was confirmed using CD20 antibody mutants to human B-cell lymphoma cells. 31548565 2019
CUI: C0079731
Disease: B-Cell Lymphomas
B-Cell Lymphomas
0.100 Biomarker group BEFREE The CD-20 antibody rituximab is a standard component of treatment of non-Hodgkin B-cell lymphomas, including diffuse large B-cell lymphoma (DLBCL). 31418878 2019
CUI: C0079731
Disease: B-Cell Lymphomas
B-Cell Lymphomas
0.100 Biomarker group BEFREE We suggest that clinicians should consider that patients with long-standing pemphigus, both vulgaris and foliaceus, may develop primary cutaneous B-cell lymphomas, as shown in our report, and in these cases the treatment with rituximab is elective, providing a therapeutic option for both low-grade or follicular, CD20-positive, B-cell non-Hodgkin lymphomas and pemphigus. 31025498 2019
CUI: C0079731
Disease: B-Cell Lymphomas
B-Cell Lymphomas
0.100 Biomarker group BEFREE CD20 is the first-line diagnostic marker of B-cells, which serves as the target of the therapeutic monoclonal antibodies in B-cell lymphomas and leukemias. 29079175 2018
CUI: C0079731
Disease: B-Cell Lymphomas
B-Cell Lymphomas
0.100 AlteredExpression group BEFREE This discussion focuses on diagnostic pitfalls related to the use of immunohistochemistry for CD20 and CD3 in hematopathology, and specifically on diagnostic challenges that arise when (1) CD20 is not expressed in B-cell lymphomas, when (2) CD20 is expressed in plasma cell neoplasms and T-cell lymphomas, and when (3) CD3 is expressed in B-cell lymphomas and Hodgkin lymphoma. 28914619 2018
CUI: C0079731
Disease: B-Cell Lymphomas
B-Cell Lymphomas
0.100 Biomarker group BEFREE Human Serum Albumin-Based Drug-Free Macromolecular Therapeutics: Apoptosis Induction by Coiled-Coil-Mediated Cross-Linking of CD20 Antigens on Lymphoma B Cell Surface. 30259654 2018
CUI: C0079731
Disease: B-Cell Lymphomas
B-Cell Lymphomas
0.100 GeneticVariation group BEFREE Survival of patients with CD20-negative variants of large B-cell lymphoma: an analysis of the National Cancer Data Base. 29019447 2018
CUI: C0079731
Disease: B-Cell Lymphomas
B-Cell Lymphomas
0.100 Biomarker group BEFREE These tumor cells were immunohistologically positive for CD10 and CD20 and negative for B-cell lymphoma (BCL) 2 and BCL6. 29678710 2018
CUI: C0079731
Disease: B-Cell Lymphomas
B-Cell Lymphomas
0.100 Biomarker group BEFREE We produced an anti-CD20-IFN fusion protein containing the potent type 1 IFN isoform alpha14 (α14), and demonstrated its ability to suppress proliferation and induce apoptosis of human B cell lymphomas. 29920129 2018
CUI: C0079731
Disease: B-Cell Lymphomas
B-Cell Lymphomas
0.100 AlteredExpression group BEFREE ENKTCL with both CD20-positive expression and the monoclonal rearrangement of IgH gene may be mistaken for B-cell lymphoma; thus, the comprehensive evaluation of histomorphology, more extensive immunoprofiles and molecular studies is essential to reach the correct diagnosis. 29063643 2018
CUI: C0079731
Disease: B-Cell Lymphomas
B-Cell Lymphomas
0.100 Biomarker group BEFREE CD20 antibody-loaded CD20<sup>+</sup> B-cell lymphoma cell lines were cultured with NK cells and ADCC activity was determined by lactate dehydrogenase release assays. 30132083 2018
CUI: C0079731
Disease: B-Cell Lymphomas
B-Cell Lymphomas
0.100 Biomarker group BEFREE The cytotoxic activity of the ADC was evaluated against Raji (human B-cell lymphoma; CD20-positive) and MOLT-4 (T lymphoblast; acute lymphoblastic leukemia; CD20-negative) cell lines. 29523024 2018
CUI: C0079731
Disease: B-Cell Lymphomas
B-Cell Lymphomas
0.100 Biomarker group BEFREE This phase II study recruited Japanese patients with previously untreated CD20+ B-cell non-Hodgkin lymphoma. 30060000 2018
CUI: C0079731
Disease: B-Cell Lymphomas
B-Cell Lymphomas
0.100 Biomarker group BEFREE slan<sup>+</sup> Monocytes and Macrophages Mediate CD20-Dependent B-cell Lymphoma Elimination via ADCC and ADCP. 29748373 2018
CUI: C0079731
Disease: B-Cell Lymphomas
B-Cell Lymphomas
0.100 Biomarker group BEFREE For the last 2 decades, anti-CD20 monoclonal antibodies have revolutionized the treatment of patients with B-cell lymphomas. 30190022 2018
CUI: C0079731
Disease: B-Cell Lymphomas
B-Cell Lymphomas
0.100 GeneticVariation group BEFREE Radioimmunotherapies with monoclonal antibodies to the B-lymphocyte antigen 20 (CD20) are effective treatments for B-cell lymphomas, but U.S. Food and Drug Administration-approved radioimmunotherapies exclusively use radiolabeled murine antibodies, potentially limiting redosing. 29348316 2018
CUI: C0079731
Disease: B-Cell Lymphomas
B-Cell Lymphomas
0.100 AlteredExpression group BEFREE Ofatumumab is a CD20 monoclonal antibody with activity against human B-cell lymphomas. 29517616 2018
CUI: C0079731
Disease: B-Cell Lymphomas
B-Cell Lymphomas
0.100 AlteredExpression group BEFREE In light of their lymphoplasmacytoid features and CD20 expression, we speculated that they may share laboratory features with B-cell lymphomas with plasmacytic differentiation (BCL-PCDs). 29214874 2018